TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03154125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sayana® Press
Description: The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
Study: NCT02436993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV over 1-3 hours weekly for 12 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
Study: NCT01260597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR intervention
Description: If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVR control
Description: If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
Study: NCT04459520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive COVID Test Result - Hypothetical Scenario
Description: Participants will be asked to imagine that they have tested positive (PCR) for an active COVID-19 infection and that their physician has clinically diagnosed them with COVID-19.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Negative COVID Test Result - Hypothetical Scenario
Description: Participants will be asked to imagine that they have tested negative (PCR) for an active COVID-19 infection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unavailable COVID Test Result - Hypothetical Scenario
Description: Participants will be asked to imagine that testing is not available for active COVID-19 infections but that their physician has clinically diagnosed them with COVID-19.
Study: NCT01191177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (omega-3-acid ethyl ester)
Description: supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: 1 gram per kilogram body weight per day, not exceeding 4 grams
Study: NCT03154125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sayana® Press
Description: The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sayana® Press
Description: The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
Study: NCT04502862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR231893
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Study: NCT01168024

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care plus peri-procedural hydration
Description: The control group will receive a peri and post-procedural hydration rate.
Study: NCT01344369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/Ethinyl Estradiol
Description: 0.4 mg/0.035 mg Chewable Tablets
Study: NCT03642249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OSCEs
Description: Scenario-based education intervention, including objective structured clinical examinations (OSCEs)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Face-to-face Education using Delirium Care Flip Chart

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lecture
Description: Face-to-face Education using Delirium Care Flip Chart

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-learning
Description: delirium care video

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-learning
Description: delirium care video
Study: NCT02984631

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preventing pulm HTN during exercise
Description: Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preventing pulm HTN during exercise
Description: Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
Study: NCT02490592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride Foam
Description: Fluoride foam - Flúor Care (NaF 1.23%) (G1)
Study: NCT03284723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06804103
Description: Dose Escalation Part - 1A Dose Expansion Part - 2A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06804103 + Palbociclib +Letrozole
Description: Dose Escalation - Part 1B Dose Expansion - Part 2B
Study: NCT01851044

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Rich Plasma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood Injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline Injection
Study: NCT00717717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
Study: NCT03309098

Intervention type: DIAGNOSTIC_TEST
Intervention: Ligmaster Arthrometer Assessment
Description: Perform an anterior drawer, inversion stress test and eversion stress test on the participant with an ankle arthrometer (LigMaster Version 1.26, Sport Tech, Inc, Charlottesville, Virginia).
Study: NCT02490592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride gel
Description: Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
Study: NCT00377208

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Intervention
Description: My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor.
Study: NCT03745521

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02235896

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education/Behavior Modification
Description: Education, lifestyle counseling, experiential cooking, exercise classes.
Study: NCT02092792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLYE5953A
Description: Escalating doses of DLYE5953A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLYE5953A
Description: Administration of DLYE5953A at the recommended phase II dose (RP2D)
Study: NCT04350996

Intervention type: OTHER
Intervention: Wearable alcohol sensor
Description: BACtrack Skyn, is a novel transdermal blood alcohol sensor developed by BACtrack, a company established for police-grade breathalyzers, and winner of the Wearable Alcohol Biosensor Challenge sponsored National Institute on Alcohol Abuse and Alcoholism.
Study: NCT01198639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform
Description: the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform
Description: an algorithm is used to maintain automatically the BIS values between 40 and 60
Study: NCT04152915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks
Study: NCT01984502

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
Description: CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
Study: NCT00458458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone Acetate (NA)
Description: 52 weeks of treatment with Norethindrone Acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH Agonist (Lupron Depot)
Description: 24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
Study: NCT01632436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixantrone
Description: Experimental Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixantrone
Description: Experimental Drug
Study: NCT02481531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Previously marketed infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Previously marketed formula using a similar protein
Study: NCT03647644

Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation Laboratory Testing
Description: Standard coagulation testing (Platelet count, Fibrinogen, PT/INR, aPTT), and Thromboelastogram as is routine and per institutional protocol in this population.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation Laboratory Testing
Description: Standard coagulation testing (Platelet count, Fibrinogen, PT/INR, aPTT), and Thromboelastogram as is routine and per institutional protocol in this population.
Study: NCT03492242

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
Study: NCT00039377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV and PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study: NCT05977764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Contrast enhanced ultrasound
Study: NCT01344369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEMCON® Fe
Description: 0.4 mg/0.035 mg Chewable Tablets
Study: NCT01364090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2b
Description: Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
Study: NCT00575237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment manouver
Description: In the intervention group, CO2 was removed by means of Trendelenburg position (\> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
Study: NCT00696215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 1 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rasagiline
Description: 1mg
Study: NCT03051672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD1 and its ligands, PD-L1 and PD-L2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: Palliative radiotherapy aims to shrink cancer, slow down its growth or control symptoms.
Study: NCT02636478

Intervention type: OTHER
Intervention: questionnaire for travel habits
Description: questionnaire has been used to collect information about travelling

Intervention type: OTHER
Intervention: questionnaire for travel habits
Description: questionnaire has been used to collect information about travelling
Study: NCT00966251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011
Description: CT-011
Study: NCT03657290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vadadustat
Description: Vadadustat Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vadadustat
Description: Vadadustat Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vadadustat
Description: Vadadustat Tablets
Study: NCT00039377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT01761019

Intervention type: DRUG
Group type: OTHER
Intervention: Taclonex Topical Suspension
Description: topical medication for psoriasis
Study: NCT00039377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01006785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1425
Description: 3 X 150 mg daily for 12 - 16 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1425
Description: 3 X 300 mg daily for 12 - 16 weeks of treatment
Study: NCT02361372

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CaCO3
Description: CaCO3 daily for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir
Description: Kefir daily for 6 months
Study: NCT04392531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard of care according to hospital protocol
Study: NCT01741558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riboflavin
Description: We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
Study: NCT03414372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tough Talks Online
Description: Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tough Talks Clinic
Description: Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
Study: NCT02899884

Intervention type: OTHER
Intervention: No Intervention
Study: NCT03833609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online yoga training (Group A)
Description: The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online aerobic dance training (Group B)
Description: The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
Study: NCT04465903

Intervention type: OTHER
Intervention: Turkish Version of Sydney Swallow Questionnaire
Description: The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.

Intervention type: OTHER
Intervention: Turkish Version of Sydney Swallow Questionnaire
Description: The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.
Study: NCT03716128

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-PET
Description: Bone biopsy and 18F-PET

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-PET
Description: Bone biopsy and 18F-PET

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-PET
Description: Bone biopsy and 18F-PET
Study: NCT04954924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized physiotherapy program and Kinesio tape
Study: NCT04630067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.